The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral
oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …

Background: The BRAFV600E mutation is the most common driver mutation in papillary
thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

Background: Mutations of v-raf murine sarcoma viral oncogene homolog B (BRAF) are
commonly identified in papillary and anaplastic thyroid carcinoma and are associated with …

The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

Abstract The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and
dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas …

Background: Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the
thyroid gland, accounting for 74–80% of all thyroid cancers. The 1799T> A transversion is an …